Cullinan Management Shares Promising Early CLN-978 Autoimmune Data

Cullinan Management ( (CGEM) ) has shared an announcement.

On May 18, 2026, Cullinan Therapeutics reported initial clinical data from two ongoing Phase 1 OUTRACE trials of CLN-978 in treatment-refractory rheumatoid arthritis and moderate to severe systemic lupus erythematosus. As of a January 14, 2026 cutoff, 14 patients had been dosed, and single subcutaneous target doses of the bispecific CD19xCD3 T cell engager produced robust B cell depletion in blood and tissue with a favorable safety profile at the starting dose levels.

Early efficacy signals included reductions in disease activity scores in most evaluable patients, with four of five RA patients showing drops in DAS28-ESR and five of six SLE patients achieving SLEDAI decreases of more than four points, alongside improved ultrasound synovitis scores in RA. Cullinan plans to present expanded data from these dose-escalation studies at the EULAR 2026 Congress in London, underscoring its bid to position CLN-978 as a differentiated, off-the-shelf option for difficult-to-treat autoimmune patients and potentially reshaping the competitive landscape for B cell–targeted therapies if results hold in later-stage trials.

The most recent analyst rating on (CGEM) stock is a Buy with a $24.00 price target. To see the full list of analyst forecasts on Cullinan Management stock, see the CGEM Stock Forecast page.

Spark’s Take on CGEM Stock

According to Spark, TipRanks’ AI Analyst, CGEM is a Neutral.

The score is held back primarily by weak financial performance driven by minimal revenue, large and increasing losses, and ongoing cash burn. This is partially offset by a low-debt balance sheet and moderately positive technical setup with the stock trading above major moving averages.

To see Spark’s full report on CGEM stock, click here.

More about Cullinan Management

Cullinan Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing potential first- or best-in-class, high-impact therapies for autoimmune diseases and cancer. Its pipeline includes CLN-978, a novel, subcutaneously administered CD19xCD3 bispecific T cell engager designed to induce potent B cell depletion and offer an off-the-shelf treatment option for conditions such as rheumatoid arthritis, systemic lupus erythematosus and Sjögren’s disease.

The company is advancing global Phase 1 programs, including the OUTRACE RA and OUTRACE SLE studies, which evaluate safety, disease activity and immune effects in heavily pretreated patients with B cell-driven autoimmune disease. These trials reflect Cullinan’s strategic focus on leveraging T cell engagers to address patients who have failed multiple prior targeted or immunosuppressive therapies and remain dependent on chronic immunosuppression.

Average Trading Volume: 860,991

Technical Sentiment Signal: Buy

Current Market Cap: $966.7M

For a thorough assessment of CGEM stock, go to TipRanks’ Stock Analysis page.